Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy

Pharmacotherapy

Volumn 20, Issue 8 II, 2000, Pages

  Cloyd, J C ^a   Remmel, R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIGARETTE SMOKE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; DIAZEPAM; DILTIAZEM; ENOXACIN; ERYTHROMYCIN; FLUCONAZOLE; FLUVOXAMINE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAMOTRIGINE; LORAZEPAM; MIDAZOLAM; NELFINAVIR; OMEPRAZOLE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RITONAVIR; SERTRALINE; TIAGABINE; VALPROIC ACID; ZONISAMIDE;

CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INHIBITION; EPILEPSY; HUMAN; STEADY STATE;

EID: 0033854906     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.12.139s.35255     Document Type: Conference Paper

References (49)

1. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazcpine: Individual variation in relation to seizure frequency and type
2. On the significance of host factors that affect drug disposition
3. Valproic acid pharmacokinetics in children. IV: Effects of age and antiepileptic drugs on protein binding and intrinsic clearance
4. Newer anticonvulsant drugs: Role of pharmacology, drug interactions and adverse reactions in drug choice
5. Clinical pharmacokinetics of new antiepileptic drugs
6. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
7. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
8. Concise review of the cytochrome P450s and their roles in toxicology
9. Cytochrome P450 isoenzymes and antiepileptic drug interactions
10. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary generalized tonic-clonic seizures
11. Phenytoin - Absorption, distribution, and excretion
12. Phenobarbital - Absorption, distribution, and excretion
13. Valproate - Absorption, distribution, and excretion
14. Valproic acid - Absorption, distribution, and excretion
15. Human liver carbamazepine metabolism: Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation
16. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites
17. Identification of enzymes responsible for the metabolism of phenobarbital
18. The fate of orally administered [4-(14C)]phenytoin in two healthy male volunteers
19. Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism
20. Clinical pharmacokinetics of valproic acid
21. The effect of aspirin on valproic acid metabolism
22. Urinary excretion of valproate and some metabolites in chronically treated patients
23. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid
24. The clinical pharmacokinetics of the newer antiepileptic drugs-focus on topiramate, zonisamide and tiagabine
25. Effects of age and gender on single-dose pharmacokinetics of gabapentin
26. A single dose and steady-state pharmacokinetic study of lamotrigine in healthy male volunteers
27. Bidirectional interaction of valproate and lamotrigine in healthy subjects
28. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy
29. Absence of pharmacokinetic drug interaction of ucb k059 (levetiracetam) with phenytoin determined by simplified stable isotope tracer technique
30. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent
31. First dose and steady-state pharmacokinetics of oxcarbazepine and its IO-hydroxy metabolite
32. Clinical pharmacology and pharmacokinetics of oxcarbazepine
33. 14C-oxcarbazepine in man
34. Evaluation of oxcarbazepine and its mono-hydroxy metabolite (GP 47779) for potential drug interactions in vitro
35. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women
36. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy
37. 14C]tiagabine by human hepatic microsomes
38. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function
39. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs
40. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate
41. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy
42. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs
43. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy
44. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for the treatment of refractory complex partial seizures
45. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data
46. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide